Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
On December 23, 2025, Dr. Reddy’s Laboratories announced that its Board of Directors will meet on January 21, 2026 to consider and approve the company’s unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. In line with securities regulations on insider trading, the company also disclosed that its trading window for dealing in its securities will be closed from December 25, 2025 to January 23, 2026, temporarily restricting trades by designated persons ahead of the quarterly earnings announcement and underscoring its compliance focus for investors across its Indian and U.S. listings.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. The firm develops, manufactures and markets generic medicines, active pharmaceutical ingredients and proprietary products, serving regulated markets including India, the United States and other international geographies through listings on the NSE, BSE, NYSE and NSE IFSC.
Average Trading Volume: 1,142,758
Technical Sentiment Signal: Buy
Current Market Cap: $11.91B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.